Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BKT14T00 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -3.28% 29.50 162,032 15:41:39
Bid Price Offer Price High Price Low Price Open Price
29.00 30.00 30.50 29.50 30.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.31 -10.92 -50.00 19
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:20 O 15,000 29.50 GBX

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
19/9/202007:24Midatech Pharma 2
17/9/202008:25Midatech Pharma (MTPH) sees 10-fold increase1,616
21/7/202012:16 Midatech Pharma Plc9
30/4/201921:51Midatech Pharma (MTPH) One to Watch 2
03/1/201712:41Midatech Pharma PLC181

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-09-22 16:08:2029.5015,0004,425.00O
2020-09-22 15:45:1828.5038,99911,114.72O
2020-09-22 15:34:2230.001,500450.00O
2020-09-22 15:32:0928.0037,91110,615.08O
2020-09-22 14:55:0929.4015,0004,410.00O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Midatech Pharma Daily Update: Midatech Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 30.50p.
Midatech Pharma Plc has a 4 week average price of 29.50p and a 12 week average price of 18.50p.
The 1 year high share price is 86.50p while the 1 year low share price is currently 1.90p.
There are currently 63,048,852 shares in issue and the average daily traded volume is 341,595 shares. The market capitalisation of Midatech Pharma Plc is £18,599,411.34.
kingston78: I am sure that the share price will double from here in a short space of time. Buy buy buy tomorrow.
kingston78: The share price has bottomed out. It is time to buy for a strong rise.
kingston78: The share price is ripe for another big push up.
kingston78: It looks like the share price has now steadied at 36 p. I think this is a turning point where it climbs up slowly towards 40-50 p range.
shujja1: Inside. share price dictates more than what meets the eye and the other point you made subscription about funding they had 2.2 million raised another 5.25 million.
mubz: What is interesting is that this chap at Paul Hasting law firm- Deyan P. Spiridonov is a member of the firm's Mergers & Acquisitions practice. So have Secura Bio done this in order to trash MTPH share price and then put in a hostile bid to takeover Please be advised that in the event that Secura Bio refuses to withdraw its purported termination notice, Midatech and Midatech Limited will vigorously pursue any and all available remedies, including claims for monetary damages based on Secura Bio's intentional wrongdoing. Midatech and Midatech Limited also reserve all rights in law and equity against Secura Bio and its agents, including, without limitation, the right to pursue tort claims (and a recovery of fees and costs in the UK) resulting from Secura Bio's intentional efforts to cause harm to and to adversely affect Midatech's market position.
kw9143: Cut & paste job from Riddier of LSE N.B --- Cut & paste job from Riddier of LSE The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases. Shares in issue : 470mln Market cap : £12mln Share price December 2019 : 2.5p Cash at June 2019 : increased by £6.70 million in the six months to 30 June . This resulted in a cash balance at the period end of £8.98 million. • February, signed first major licence deal, with Chinese specialty pharmaceutical group, China Medical System ("CMS") . CMS is listed on the Hong Kong Stock Exchange (HK:867) with a market capitalisation of approximately HK$18.40 billion (c. £1.797 billion) as at 28 January 2019. The CMS Group had revenues of RMB 5,348.8 million (c. £600.2 million) • Strategic investment in the Company by China Medical System ("CMS") and an associated party of CMS (A&B (HK) Company Ltd ("A&B")) of £8 million (gross proceeds) in aggregate, plus agreement to licence the Group's pipeline products in the Greater China Area and certain South East Asian countries. They hold 20% of the share register as of 5th Nov 2019. • 8th October RNS their dosing of patients for their Neuro cancer trials was completed and they go on to say "Following MTD201 dosing, all subjects enter a 63 day observation and sampling period. This data will then be analysed, with top line results expected by the end of 2019 or early in 2020." • $2mln placing 3.9p Nov 2019 through a direct offering of 3,000,000 of its American Depositary Shares ("ADSs") (each ADS representing 20 of the Company's ordinary shares.) And with warrants excercisable at 4.8p • Grant funded project €2.6mln announced Dec 5th - rose 40% from 2.7p to 3.9p but fell back due to the seller ( which i assume to be ex Woodford stock controlled by LinkFund) • "Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer" and later goes on to re-confirm "Orphan Drug Status for this ultra-rare disease was granted for MTX110 in the US this year providing for a potentially more rapid approval process" • Spanish Government loan to further support the Group's manufacturing scale-up capabilities. If successful, it is expected that the loan will cover up to 75% of the manufacturing scale-up cost of approximately €15 million. The outcome expected around end of H1 2019. • Efforts are ongoing to pursue out-licence opportunities that secure up-front payments, particularly for MTD201 and the Q-Sphera platform.m • Link fund have 16% ( 77,825,626) as of 30th Oct. This has created a drag on the share price since mid 2019 and is now 40% below the November • Volume accelerated last 2 days e.g 6mln Thursday and now 4.5mln Friday.
sam_: From LSE board this evening: "I just saw the following on Stocktwits which is a US social media platform designed for sharing ideas between investors and traders. Someone on there emailed Tim Metcalfe (Investor Relations at Midatech Pharma) in regards to the share price reaction to the RNS and this was the respond received: " Hi Jeff Don’t worry, I share your frustrations! As well as being an adviser to the company, I am also a shareholder. The stock was up 45% in London in the hour after the announcement went out, an appropriate response in my view, only to close only 3% up following the Nasdaq trading and its obviously gone down further since London close. We live in interesting times and I unfortunately see on numerous occasions here where good news creates liquidity and the sellers take advantage, ultimately pushing the price down. This was very good news today and I will be looking in detail at what’s happened in the market and what, if anything, the company can do to address the issues. All I can do is thank you for your support and patience. Best regards Tim" Screenshot : www. i.imgur .com /MPpNsq5.png "
Midatech Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200923 03:03:45